Open Access

131I-Traced PLGA-Lipid Nanoparticles as Drug Delivery Carriers for the Targeted Chemotherapeutic Treatment of Melanoma

Nanoscale Research Letters201712:365

DOI: 10.1186/s11671-017-2140-7

Received: 13 April 2017

Accepted: 12 May 2017

Published: 19 May 2017


Herein, folic acid (FA) conjugated Poly(d,l-lactide-co-glycolide) (PLGA)-lipid composites (FA-PL) were developed as nanocarriers for the targeted delivery of insoluble anti-cancer drug paclitaxel (PTX), resulting FA-PLP nanoparticles. Furthermore, 131I, as a radioactive tracer, was used to label FA-PLP nanoparticles (FA-PLP-131I) to evaluate their cell uptake activity, in vivo blood circulation, and biodistribution. The FA-PLP-131I nanoparticles had a spherical morphology with great stability, a narrow size distribution (165.6 and 181.2 nm), and −22.1 mV in average zeta potential. Confocal laser scanning microscopy indicated that the targeting molecule FA promotes PLP-131I uptake by melanoma B16F10 cells, which was further confirmed by the cell incorporation rate via 131I activity detection as measured by a gamma counter. FA-PLP-131I without PTX (FA-PL-131I) shows minor cytotoxicity, good biocompatibility, while FA-PLP-131I was demonstrated to have efficient cell viability suppression compared to free PTX and PLP-131I. Following intravenous injection, the blood circulation half-life of free PTX (t 1/2 = 5.4 ± 0.23 h) was prolonged to 18.5 ± 0.5 h by FA-PLP-131I. Through FA targeting, the tumor uptake of FA-PLP-131I was approximately 4.41- and 12.8-fold higher compared to that of PLP-131I and free PTX-131I, respectively. Moreover, following 40 days of treatment, FA-PLP-131I showed an improved tumor inhibition effect compared to free PTX and PLP-131I, with no relapse and no remarkable systemic in vivo toxicity. The results demonstrate that the 131I-labeled PLGA-lipid nanoparticle can be simultaneously applied for targeted drug delivery and reliable tracking of drugs in vivo.


Nanocarrier PLGA-lipid 131I Biodistribution Drug delivery Melanoma


One of the most aggressive skin cancers, melanoma, originates from the malignant transformation of melanocytes [1, 2]. Given its easy relapse and high potential for metastasis, the 5-year survival of metastasized melanoma patients is only 10%. To date, the most common treatment for melanoma patients is chemotherapy, which is accompanied by undesirable severe side effects, low bioavailability, poor tumor selectivity, and dose-limiting systemic toxicity, presenting major challenges in tumor chemotherapy [3, 4].

Paclitaxel (PTX), a natural plant extract derived from the dried roots, branches, leaves, and bark of taxus, a genus of coniferous trees [5, 6], shows effective antitumor activity towards several kinds of tumors, including ovarian carcinoma and lung cancer [79]. Additionally, PTX has also been reported as efficient against human melanoma [10, 11]. Nevertheless, in addition to the abovementioned drawbacks of chemotherapeutic drugs, a Cremophor EL and dehydrated alcohol (1:1, v/v) mixture is used in current clinical practice as the dilution medium for PTX, which may lead to serious side effects, including hypersensitivity [12, 13]. Therefore, the development of novel strategies to enhance the aqueous solubility and tumor accumulation of chemotherapeutic agents to reduce their peripheral exposure and minimize their in vivo toxicity is paramount. The recent development of biocompatible drug nanocarriers provides the potential to enhance the physiological stability of PTX [1416]. Additionally, the conjugation of target molecules to these nanocarriers would allow the selective delivery of chemotherapeutic agents to tumor sites with reduced peripheral exposure through a tumor cell surface receptor-mediated targeted effect [1719].

Herein, we prepared a Poly(d,l-lactide-co-glycolide) (PLGA)-lipid composite that covalently conjugates folic acid (FA: a tumor targeting molecule) and encapsulates PTX as a chemotherapeutic drug for melanoma treatment. Moreover, 131I, a radioactive marker, was used to radiolabel the PLGA-lipid nanoparticles to clearly assess their in vivo behavior. Because of its negative beta emission, physical half-life, and wide range of decay properties, 131I is commonly used as a radiolabel in clinic [2022]. The morphology, stability, and dispersity of the 131I-labeled PLGA-lipid nanoparticles (FA-PLP-131I) were evaluated in vitro. Furthermore, the cell uptake, blood circulation, and biodistribution of FA-PLP-131I were investigated by measuring the radioactivity of 131I. Moreover, the targeted anticancer efficacy of FA-PLP-131I was studied in vitro and in vivo. The results indicate that FA-PLP-131I may be a versatile nanoplatform for use as a potential tumor drug delivery nanocarrier for chemotherapeutic drugs.



Poly(d,l-lactide-co-glycolide) (PLGA, MW: 5000–15,000, lactide:glycolide (50:50)) and chloramine-T were purchased from Sigma Aldrich (St. Louis, MO, USA). Na131I was obtained from Atomic Hitech (Beijing, China). PTX (99%) and 4′,6-diamidino-2-phenylindole (DAPI) were purchased from Aladdin Chemical Reagent Co., Ltd. (Shanghai, China). Soybean lecithin consisting of 90–95% phosphatidylcholine, 1,2-distearoyl-sn-glycerol-3-phosphoethanolamine-N-[folate (polyethylene glycol)-2000] (DSPE-PEG2000-FA), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxy (polyethylene glycol)-2000] (DSPE-PEG2000-COOH) were obtained from Avanti (Alabaster, AL, USA). All cell culture reagents were purchased from Sigma Aldrich.

Preparation of FA-PLP Nanoparticles

FA-PLP nanoparticles were synthesized by a self-assembly nanoprecipitation method [23]. In detail, 10 mg PTX was dissolved in 1 mL ethanol and 2 mg PLGA was dissolved in 1 mL dichloromethane. Following mixing them, lecithin/DSPE-PEG2000-FA (4:1) ethanol aqueous solution (4 wt%) was added drop-wise into the mixture solution for 4 h gentle stirring at 25 °C. The mixture was filtered and washed three times with deionized water using a Millipore ultrafiltration centrifuge tube to remove the non-encapsulated drug and organic solvent. As a control, nanoparticles without FA molecule grafting were prepared through the same method, replacing DSPE-PEG2000-FA with DSPE-PEG2000-COOH. The purified FA-PLP nanoparticles were stored at 4 °C until further use.

Preparation of 131I-Labeled FA-PLP Nanoparticles

Radioactive FA-PLP (FA-PLP-131I) nanoparticles were prepared through the chloramine-T oxidation method [24]. A mixture of 1 mL FA-PLP (1 mg/mL), 500 μCi Na131I (which is the maximum radioactivity that can be grafted onto FA-PLP), and 100 μL of 5 mg/mL chloramine-T were reacted in a pH 7.5 phosphate buffer for 10 min at room temperature. The reaction was then quenched by adding 200 μL of sodium metabisulfite (5 mg/mL). 131I-labeled PLP and PTX were prepared following the same procedure. They were purified using a centrifuge tube (Millipore) to remove the remaining free Na131I until no gamma activity was detectable in the filtrate solution. The radiolabeling yield and purity of the labeled nanoparticles were analyzed using a gamma counter (LKB gamma 1261; LKB Instruments).


UV–vis absorption spectra were recorded using a UV–vis spectrophotometer (UV7502, Shanghai Advanced Photoelectric Technology Co., Ltd., Shanghai, China). Transmission electron microscopy (TEM) images were collected on a Zeiss LIBRA 120 TEM. The size, zeta potential, and polydispersity index (PDI) of nanoparticles were detected by dynamic light scattering (DLS) analysis using a Zetasizer Nano ZS (Malvern Instruments). Optical photographs were taken with a Nikon D3200 digital camera.

Cell Culture

The mouse melanoma cell line B16F10 was obtained from the Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and cultured in DMEM containing 10% fetal bovine serum and 100 U/mL of penicillin/streptomycin in a humidified 5% CO2 atmosphere at 37 °C.

In Vitro Incorporation Assays

Time-dependent in vitro incorporation assays were performed to determine the optimum cell binding efficiency times for the 131I-labeled compounds [25]. B16F10 cells were seeded in 24-well plates at 1 × 105 cells per well and cultured to confluence. Radioiodinated samples (131I, PL-131I, FA-PL-131I, PLP-131I, FA-PLP-131I) were prepared in DMEM media and added to the cell culture wells, separately. After 0.5, 1, 2, 4, and 6 h incubation, the cells were washed with PBS three times and their radioactivity measured with a gamma counter (Science and Technology Institute of China, Jia Branch Innovation Co., Ltd.). Incorporation values (%) were calculated as described in the previous literature [25]. Additionally, nanoparticles were labeled with the fluorescent dye fluorescein isothiocyanate (FITC, Sigma) and then incubated with B16F10 cells. The fluorescence images of cells were captured using a commercial confocal laser scanning microscope (FV1200, Olympus, Tokyo, Japan).

In Vitro Cytotoxicity Assay

The MTT cell viability assay was used to study the cytotoxicity of PL-131I and FA-PL-131I, as well as that of free PTX, PLP-131I, and FA-PLP-131I, against B16F10 cells. Briefly, B16F10 cells were plated in 96-well plates for 24 h and exposed to PL-131I and FA-PL-131I (with 0–100 μg/mL PLGA-lipid), or free PTX, PLP-131I, and FA-PLP-131I (at various concentrations of 0–40 μg/mL) for 24 h. The experiment was performed in triplicate. All data were expressed as the mean ± SD.

Animal Model

Three- to 5-week-old Balb/c mice were purchased from Shanghai Slack Laboratory Animal Co., Ltd. (Shanghai, China). All animal experiments were approved by the Animal Care and Use Committee of Fudan University, which complies with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

B16F10 cells (1 × 106) in PBS were injected subcutaneously into the right flank of mice. The growing tumor volume was measured using a caliper, and the tumor volume was calculated using the formula: volume = (length × width2)/2. When the tumor volume reached approximately 80 mm3, the mice were randomized into the experimental groups.

Blood Circulation and Biodistribution Study

Healthy Balb/c mice were intravenously injected with PTX-131I and FA-PLP-131I (100 μL of 10 μCi per mouse, 5 mg/kg). Blood circulation was measured by drawing approximately 10 μL of blood from the tail of mice. The radioactivity in blood was measured using a gamma counter. In order to detect the nanoparticle biodistribution, mice bearing a B16F10 tumor were injected with PTX-131I, FA-PL-131I, PLP-131I, and FA-PLP-131I at the same dose and sacrificed 24 h after injection. The major organs were weighed and collected for gamma counting.

In Vivo Tumor Chemotherapy

Balb/c mice bearing B16F10 tumors were injected with 150 μL of saline, free PTX, PLP-131I, and FA-PLP-131I (at the same PTX concentration, 5 mg/kg). The tumor size and body weight were measured by a caliper every 4 days. Relative tumor volumes were calculated as V/V 0 (V 0 was the tumor volume when the treatment was initiated). After approximately 40 days of treatment, mice were sacrificed and the major organs collected, fixed in 4% formalin, paraffin embedded and sliced, stained with hematoxylin and eosin, and examined under a digital microscope.

Results and Discussion

Preparation and Characterization of 131I-Labeled FA-PLP Nanoparticles

The synthesis scheme of FA-PLP-131I nanoparticles is shown in Fig. 1. In brief, FA-PLP nanoparticles were synthesized through a self-assembly nanoprecipitation method and radioactive FA-PLP (FA-PLP-131I) was prepared using the chloramine-T oxidation method [23, 24]. PTX was encapsulated by the PLGA-lipid composite, which was then grafted with covalent conjugated FA on the surface of the shell via PEGylation. Finally, 131I was grafted onto the outer nanoparticle surface. TEM images indicated that the FA-PLP-131I nanoparticles had a spherical morphology of narrow size distribution (165.6 to 181.2 nm), which was confirmed by dynamic light scattering (Fig. 2a, b). The zeta potential ranged from −39.1 to −3.2 mV (Fig. 2c). The UV–vis spectra of free PTX and FA-PLP-131I (with same concentration of PTX) showed the same feature peak at 233 nm (Fig. 2d), indicating that PTX had been encapsulated within FA-PLP-131I and that encapsulation did not influence the absorbance intensity of PTX. After calculation, the encapsulation efficiency of PTX in FA-PLP-131I was shown to be 56.35 ± 1.6%. The radiolabeling yield of PTX-131I, PL-131I, FA-PL-131I, PLP-131I, and FA-PLP-131I was 45.6 ± 2.3, 52.1 ± 4.1, 48.9 ± 1.9, 56.3 ± 2.5, and 54.8 ± 2.7, respectively.
Fig. 1

Synthesis of FA-PLP-131I nanoparticles

Fig. 2

a TEM image of FA-PLP-131I. b Particle size and c zeta potential of FA-PLP-131I analyzed by dynamic light scattering. d Absorbance spectra of free PTX and FA-PLP-131I

Stability is essential to the biomedical application of nanoparticles [26]. After 4 weeks in storage, FA-PLP-131I dissolved in water, cell media, fetal bovine serum, and PBS displayed no changes in average size, zeta potential, PDI index (Fig. 3a–c), indicating great stability and dispersity. In addition, the radiolabeling stability of FA-PLP-131I was detected in mouse plasma at 37 °C (Fig. 3d), showing less than 15% de-iodination within 7 days.
Fig. 3

a, b Colloid stability and c PDI test of FA-PLP-131I in different media, including water, DMEM, PBS, and fetal bovine serum (FBS). d Radiolabeling stability curve of FA-PLP-131I in mouse plasma at 37 °C within 2 weeks of storage

In Vitro Cellular Uptake

Figure 4 shows the in vitro time-dependent incorporation of 131I, PL-131I, FA-PL-131I, PLP-131I, and FA-PLP-131I in B16F10 cells measured by a gamma counter. FA-PLP-131I, as well as FA-PL-131I, showed the higher incorporation values than that of all tested time points, increasing with time. The incorporation values of FA-PLP-131I at 6 h were 3.12- and 23.4-fold higher than those of 131I and PLP-131I, in agreement with the results of confocal laser scanning microscopy images of B16F10 cells incubated with fluorescein isothiocyanate-labeled FA-PLP-131I and PLP-131I nanoparticles (Additional file 1: Figure S1). These results demonstrate the high cellular uptake of FA-PLP-131I, likely due to the FA-mediated targeting effect on B16F10 cells.
Fig. 4

Time-dependent incorporation of 131I, PL-131I, FA-PL-131I, PLP-131I, and FA-PLP-131I on B16F10 cells

In Vitro Cytotoxicity

The cytotoxicity of the control nanocarriers, PL-131I, and FA-PL-131I was tested by MTT assay. Cells treated with PL-131I and FA-PL-131I for 24 h had a similar viability to the control (Fig. 5a), indicating a good biocompatibility. Additionally, FA-PLP-131I was much more effective at suppressing B16F10 cell proliferation than free PTX and PLP-131I at the same concentration of PTX (Fig. 5b), indicating excellent cell-targeted chemotherapy. The results demonstrate that FA-PLP-131I has a high chemotherapeutic effect with no radiotoxicity and cytotoxicity.
Fig. 5

a Cell viability of B16F10 cells after treatment with PL-131I and FA-PL-131I for 24 h. b Cell viabilities of B16F10 cells after incubation with different concentrations of free PTX, PLP-131I, and FA-PLP-131I for 24 h

Blood Circulation and Biodistribution Study

Radiolabeling has been reported to be more reliable than fluorescence imaging for the quantitative and accurate in vivo tracking of nanoparticles [27, 28]. 131I-labeled FA-PLP nanoparticles were prepared to investigate their in vivo behavior, including blood circulation and biodistribution, as measured by a gamma counter. The blood circulation half-life of free PTX (t 1/2 = 5.4 ± 0.23 h) was prolonged to 18.5 ± 0.5 h by FA-PLP-131I (Fig. 6a) due to nanoparticle encapsulation, which was favorable for tumor targeting accumulation [2931]. Next, the biodistribution of free PTX-131I, PLP-131I, and FA-PLP-131I in B16F10 tumor-bearing mice at 1 day post injection was investigated (Fig. 6b). FA-PLP-131I, as well as FA-PL-131I, exhibited an obvious enhancement of tumor uptake, which was 4.41- and 12.8-fold than that of PLP-131I and free PTX-131I, respectively, likely due to the prolonged blood circulation of FA-PLP-131I, FA-PL-131I, and its FA targeting effect. In addition, the liver and spleen also exhibited a relatively high uptake due to their nanoparticle metabolism, which were the normal metabolic organs [32, 33].
Fig. 6

a The blood circulation curve of FA-PLP-131I after intravenous injection. b Biodistribution of PTX-131I, FA-PL-131I, FA-PLP-131I, and PLP-131I in B16F10 tumor-bearing mice

In Vivo Tumor Chemotherapy

Free PTX-, PLP-131I-, and FA-PLP-131I-treated mice exhibited inhibition of tumor growth as compared to the saline control group (Fig. 7a). Overall, FA-PLP-131I was the most effective at tumor growth suppression without relapse compared to all treated groups after approximately 40 days of treatment. These results are as expected considering the significantly prolonged blood circulation of FA-PLP-131I and therefore its ability to promote FA-mediated tumor targeted accumulation. Further, tumor-targeted accumulation also led to a reduction in peripheral exposure of PTX, thereby minimizing systemic toxicity. As expected, over the complete treatment process, there was no noticeable loss in body weight (Fig. 7b), and the major organs, including the heart, liver, spleen, lung, and kidney, showed no obvious histological lesions in any group (Fig. 7c).
Fig. 7

a The relative tumor volume and b body weight of tumor-bearing mice after tail vein injection with saline (control), free PTX, PLP-131I, and FA- PLP-131I. b Body weight of tumor-bearing mice after tail vein injection with saline (control), free PTX, PLP-131I, and FA- PLP-131I. c The representative hematoxylin and eosin staining images of major organs including the heart, liver, spleen, lung, and kidney. Scale bar = 100 μm


In summary, we have synthesized 131I-labeled PLGA-lipid nanoparticles as drug delivery carriers for melanoma-targeted chemotherapy. By measuring the radioactivity of 131I, the in vitro and in vivo behaviors of FA-PLP-131I nanoparticles were studied. The obtained FA-PLP-131I showed great dispersity and colloidal and radiolabeling stability. The control nanocarriers, PL-131I, and FA-PL-131I also showed good biocompatibility. Following encapsulation of PTX, FA-PLP-131I was the most effective at suppressing B16F10 cell proliferation without cytotoxicity, attributed to the FA targeting effect. Moreover, FA-PLP-131I was demonstrated to significantly prolong the blood circulation of PTX and to effectively accumulate within the targeted tumor region. Thus, FA-PLP-131I had an excellent tumor growth inhibition and great in vivo biocompatibility. The results highlight the promising potential of these versatile FA-PLP-131I nanocarriers as reliable drug tracking agents as well as their application in tumor targeted therapy.


Authors’ Contributions

HYW conducted the experiments and WZS wrote the manuscript. All authors read and approved the final manuscript.

Competing Interests

The authors declare that they have no competing interests.

Ethics Approval

All animal experiments were approved by the Animal Care and Use Committee of Fudan University, which complies with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

Department of Nuclear Medicine, Shanghai East Hospital, Tongji University School of Medicine
Department of General Surgery, Zhongshan Hospital, Fudan University


  1. Kim DW, Patel SP (2014) Profile of selumetinib and its potential in the treatment of melanoma. Onco Targets Ther 7:1631–1639Google Scholar
  2. Shain AH, Bastian BC (2016) From melanocytes to melanomas. Nat Rev Cancer 16:345–358View ArticleGoogle Scholar
  3. Ma C, Armstrong AW (2014) Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatolog Treat 25:401–408View ArticleGoogle Scholar
  4. Chidambaram M, Manavalan R, Kathiresan K (2011) Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci 14:67–77View ArticleGoogle Scholar
  5. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K (2013) Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 14:1020–1026View ArticleGoogle Scholar
  6. Wang T, Liu Y, Wu C (2017) Effect of paclitaxel-mesoporous silica nanoparticles with a core-shell structure on the human lung cancer cell line A549. Nanoscale Res Lett 12:66View ArticleGoogle Scholar
  7. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB (2002) Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62:1087–1092Google Scholar
  8. Lv S, Tang Z, Li M, Lin J, Song W, Liu H, Huang Y, Zhang Y, Chen X (2014) Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Biomaterials 35:6118–6129View ArticleGoogle Scholar
  9. Komiya K, Nakamura T, Nakashima C, Takahashi K, Umeguchi H, Watanabe N, Sato A, Takeda Y, Kimura S, Sueoka-Aragane N (2016) sParc is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer. Onco Targets Ther 9:6663–6668View ArticleGoogle Scholar
  10. Azzarito T, Venturi G, Cesolini A, Fais S (2015) Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Lett 356:697–703View ArticleGoogle Scholar
  11. Wilson MA, Zhao F, Khare S, Roszik J, Woodman SE, D'Andrea K, Wubbenhorst B, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL (2016) Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanoma. Clin Cancer Res 22:374–382View ArticleGoogle Scholar
  12. Szebeni J, Alving CR, Muggia FM (1998) Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 90:300–306View ArticleGoogle Scholar
  13. Šmejkalová D, Nešporová K, Hermannová M, Huerta-Angeles G, Cožíková D, Vištejnová L, Safránková B, Novotný J, Kučerík J, Velebný V (2014) Paclitaxel isomerisation in polymeric micelles based on hydrophobized hyaluronic acid. Int J Pharm 466:147–155View ArticleGoogle Scholar
  14. Zhang F, Zhang S, Pollack SF, Li R, Gonzalez AM, Fan J, Zou J, Leininger SE, Pavía-Sanders A, Johnson R, Nelson LD, Raymond JE, Elsabahy M, Hughes DM, Lenox MW, Gustafson TP, Wooley KL (2015) Improving paclitaxel delivery: in vitro and in vivo characterization of PEGylated polyphosphoester-based nanocarriers. J Am Chem Soc 137:2056–2066View ArticleGoogle Scholar
  15. Xu Z, Wang S, Li Y, Wang M, Shi P, Huang X (2014) Covalent functionalization of graphene oxide with biocompatible poly(ethylene glycol) for delivery of paclitaxel. ACS Appl Mater Interfaces 6:17268–17276View ArticleGoogle Scholar
  16. Di Costanzo F, Gasperoni S, Rotella V, Di Costanzo F (2009) Targeted delivery of albumin bound paclitaxel in the treatment of advanced breast cancer. Onco Targets Ther 2:179–188View ArticleGoogle Scholar
  17. Danhier F, Feron O, Préat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135–146View ArticleGoogle Scholar
  18. Paulos CM, Turk MJ, Breur GJ, Low PS (2004) Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev 56:1205–1217View ArticleGoogle Scholar
  19. Pérez-Herrero E, Fernández-Medarde A (2015) Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52–79View ArticleGoogle Scholar
  20. Cook BE. The use of radioactive nanoparticles for the diagnosis and treatment of cancer. The Alfred University 2014.
  21. Unak P, Cetinkaya B (2005) Absorbed dose estimates at the cellular level for 131I. Appl Radiat Isot 62:861–869View ArticleGoogle Scholar
  22. Yi X, Yang K, Liang C, Zhong X, Ning P, Song G, Wang D, Ge C, Chen C, Chai Z, Liu Z (2015) Imaging-guided combined photothermal and radiotherapy to treat subcutaneous and metastatic tumors using iodine-131-doped copper sulfide nanoparticles. Adv Funct Mater 25:4689–4699View ArticleGoogle Scholar
  23. Xin Y, Liu T, Yang C (2016) Development of PLGA-lipid nanoparticles with covalently conjugated indocyanine green as a versatile nanoplatform for tumor-targeted imaging and drug delivery. Int J Nanomedicine 11:5807–5821View ArticleGoogle Scholar
  24. Gao J, Fang L, Sun D, Shen Y, Hu Y, Li N, Chang J, Li W, Tan J (2016) 131I-labeled and DOX-loaded multifunctional nanoliposomes for radiotherapy and chemotherapy in brain gliomas. Brain Res. doi:10.1016/j.brainres.2016.12.014 Google Scholar
  25. Akman L, Muftuler FZB, Bilgi A, Kilcar AY, Gokulu SG, Medine EI, Terek MC (2016) Synthesis of a theranostic agent: radioiodinated PEGylated PLGA-indocyanine capsules and in vitro determination of their bioaffinity on ovarian, cervical and breast cancer cells. J Radioanal Nucl Chem 308:659–670View ArticleGoogle Scholar
  26. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161:505–522View ArticleGoogle Scholar
  27. Shokeen M, Fettig NM, Rossin R (2008) Synthesis, in vitro and in vivo evaluation of radiolabeled nanoparticles. Q J Nucl Med Mol Imaging 52:267–277Google Scholar
  28. Yang K, Wan J, Zhang S, Tian B, Zhang Y, Liu Z (2012) The influence of surface chemistry and size of nanoscale graphene oxide on photothermal therapy of cancer using ultra-low laser power. Biomaterials 33:2206–2214View ArticleGoogle Scholar
  29. Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, Dai H (2008) Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 68:6652–6660View ArticleGoogle Scholar
  30. Torchilin V (2011) Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 63:131–135View ArticleGoogle Scholar
  31. Gabizon AA (1995) Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Adv Drug Deliv Rev 16:285–294View ArticleGoogle Scholar
  32. Kulkarni SA, Feng SS (2013) Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res 30:2512–2522View ArticleGoogle Scholar
  33. Wang J, Xie Y, Wang L, Tang J, Li J, Kocaefe D, Kocaefe Y, Zhang Z, Li Y, Chen C (2015) In vivo pharmacokinetic features and biodistribution of star and rod shaped gold nanoparticles by multispectral optoacoustic tomography. RSC Adv 5:7529–7538View ArticleGoogle Scholar


© The Author(s). 2017